Multidisciplinary Therapy Managed Recurrent Glioblastoma in a BRAF-V600E Mutant Pregnant Female: A Case Report and Review of the Literature

Chaoying Qin¹, Wenyong Long¹, Chi Zhang¹, Yuanyang Xie¹, Changwu Wu¹, Yang Li¹, Qun Xiao¹, Nan Ji² and Qing Liu¹*¹

¹ Department of Neurosurgery in Xiangya Hospital, Central South University, Changsha, China, ² Department of Neurosurgery in Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Background: Glioblastoma (GBM) is the most malignant intracranial tumor in adults. However, the overall management of GBM in pregnancy is rarely reported. How to balance the therapeutic benefits to the mother and risks to the fetus remains hugely challenging for clinicians. The application of specific targeting therapy combined with conventional treatment sheds light on a longer lifetime for the patients suffering from GBM.

Case Presentation: We present a pregnant female at 20 weeks gestation diagnosed with GBM. Surgical resection was initially performed without adjuvant therapy, and the tumor recurred de novo 2 months later. A secondary craniotomy and cesarean section were performed simultaneously at 32 weeks gestation, both the patient and infant were survived. She was subsequently treated with traditional chemo-radiotherapy. No other identified genetic alterations indicating an optimistic prognosis were detected except for BRAF V600E mutation. Thus, the BRAF inhibitor was placed on her with achieving a good clinical outcome of more than 2-year survival without recurrence.

Conclusion: Personalized multidisciplinary therapy should be considered when GBMs occur in pregnancy. Response to the therapy in this presenting case suggests that BRAF V600E mutation is a favorable biomarker for GBM. The mortality of GBM might be reduced through genetic testing and targeted treatment. However, more studies must be conducted to confirm our observation.

Keywords: glioblastoma (GBM), pregnancy, multidisciplinary therapy (MDT), BRAF V600E, vemurafenib

BACKGROUND

Glioblastoma (GBM) is the most aggressive brain tumor which is considered a grade IV glioma based on the WHO classification (1), with a median survival of only 3 months in untreated patients (2) and 15 months after conventional therapy (3, 4). Pregnancy diagnosed with GBM is rarely reported; how to balance the therapeutic benefits to the mother, and harmful effects to the fetus is exceptionally challenging for clinicians. The craniotomy is highly risky for both pregnant patients...
and the fetus. Moreover, radio-chemotherapy is associated with impaired ovarian function, which may impact normal physical development of the embryo (5, 6). To date, the optimal timing of surgery, the utilization of radio-chemotherapy in pregnancy remains deeply controversial (7), and the prognosis of GBM during any stages of pregnancy is extremely poor. Thus, the management of GBM presenting during pregnancy is of great importance to the patient, fetus, family, and clinicians of multidisciplinary teams (8).

With the innovation of genomic characterization, more profound insights into the molecular identity of tumors have been achieved. Increasing molecular targets aiming at the stages of initiation, development, and metastasis of tumors have been identified, through which various novel targeted treatment regimens are created. Multidisciplinary therapies that are composed of targeted therapies, surgery, radiotherapy, and adjuvant chemotherapy have shown efficacy in multiple malignant entities including tumors of the central nervous system (9, 10). The proto-oncogene B-Raf (BRAF) encodes a serine/threonine-protein kinase of the RAS-RAF-MEK-ERK MAP kinase pathway. This highly regulated pathway controls cell growth and can be disrupted by BRAF alterations. The majority of BRAF mutations are missense mutations at amino acid position 600 that generate a protein with a glutamic acid (E) residue substituted for the normal valine (V) residue (BRAF V600E). The constitutively activated form of BRAF results in excessive cell proliferation, subsequently promoting tumor growth (11, 12). It has been documented that leukemia (13, 14), colorectal cancer (15), and non-small cell lung cancer (16, 17) contain BRAF mutation. Importantly, successful regression in tumors including melanoma (18) and craniopharyngioma (19) with BRAF inhibitors such as vemurafenib has been reported. The occurrence of BRAF mutation in glioblastoma is rare, which was found in 2 out of 34 (6%) glioblastoma patients (20, 21). A study reported by Ceccon et al. manifested that BRAF targeted therapy could become an optional approach for GBM patients, especially for those with chemo-resistance or radiotherapy intolerance (18, 22). However, to the best of our knowledge, no data about BRAF inhibitors toward pregnancy with GBM is reported yet.

Here, we present the first case of a young pregnant female with glioblastoma exhibiting BRAF V600E mutation, in whom the isocitrate dehydrogenase (IDH1), O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and telomerase reverse transcriptase (TERT) are all negative, indicating chemo-resistance to the classical chemotherapy strategy. The tumor was short-term recurrent after the primary surgical resection without concomitant therapy. Multidisciplinary therapy composing of mainstream modality for glioma revolved around the second surgery, radiation, chemotherapy and molecular therapy using BRAF V600E inhibitor, was placed on her, resulted in stable regression of the tumor for more than 2 years so far. Besides, the management of GBMs in pregnancy that were reported in the literature were also reviewed and summarized.

**CASE PRESENTATION**

A 28-year old female at 20 weeks’ gestation was admitted to our hospital with progressive headache, dizziness, emesis and vision diminution for 2 months. Magnetic resonance imaging (MRI) showed a heterogeneous cystic and solid mass in the right parietal lobe with marked surrounding edema and a shift of the midline structures to the left side; the cyst wall is distinctly enhanced with contrast medium. GBM was highly suspected (Figure 1A). Total resection of the tumor was performed (Figure 1B) with histopathological diagnose of GBM (Figure 1C). Immunohistochemistry exhibited the proliferation marker ki67 was up to 10%, MGMT low methylation, and no IDH1/2 mutation was detected, indicating the tumor was highly aggressive with fairly poor prognosis. With respect to the patient’s own will, no radiation therapy or concomitant chemotherapy was applied after surgery.

Unfortunately, over 2 months after the operation (32 weeks gestation), with complaints of dizziness and headache, the patient was transferred to our hospital again. An emergency CT scan supported tumor recurrence (Figure 1D). B-mode ultrasonography showed the fetus was healthy with matured lung. The next day, the patient presented loss of consciousness and right mydriasis all of a sudden. After emergent dehydration treatment, cesarean section and second craniotomy (Figure 1E) were performed contemporarily. Both the mother and infant were survived. Once again, the pathological diagnosis was GBM (Figure 1F), but ki67 was more than 30%, suggesting the recurrent tumor was more aggressive and contained a higher risk of relapse than the primary tumor. Traditional RT and chemotherapy were placed on the patient (Table 2). Considering the short-term recurrence after the first total resection, Ki67 jumped to 30% + from 10% + in addition, gene sequencing was performed for the patient, which demonstrated no MGMT methylation or IDH mutation (R132H and non-canonical). But BRAF V600E mutation was detected Table 3, showing targeted therapy with BRAF inhibitor may bring benefits for the patient. Thus, vemurafenib was applied (720 mg, twice a day for 28 days), well-tolerance except for the diffuse palpable follicular rashes was achieved. Follow-up MRI showed stable disease with no recurrence in the right parietal area (Figure 1G). It has been more than 2 years from the initiation of the multidisciplinary therapy to the latest follow-up examination. The life quality of the patient was satisfied with a healthy baby in the meantime. The regular follow-up information is exhibited as supplementary data (Supplementary Figures 1–4).

**Literature Review**

The management of GBMs in pregnancy were diverse and customized, which was highlighted by a literature review of published cases (Table 1). We conducted a PubMed search using glioblastoma/GBM AND (“pregnancy” OR “gestation”)

---

**Abbreviations:** MDT, multidisciplinary therapy; GBM, glioblastoma; WHO, world health organization; TMZ, temozolomide; IDH1, the isocitrate dehydrogenase-1; MGMT, O-6-methylguanine-DNA methyltransferase; TERT, telomerase reverse transcriptase; RT, radiation therapy; C/S, cesarean section; EGFR, epidermal growth factor receptor; PXA, pleomorphic xanthoastrocytoma.
and selected “clinical study” and “case report” as the article type. These search terms yielded 10 previous case reports of GBMs in variant stages of pregnancy and the personalized treatment strategy placed on those cases.

Some of the pregnant patients chose to get RT and/or chemotherapy after surgical resection by taking a risk for the fetus even at the metaphase of gestation. In the case reported in 2012 (5), the 14-week gravida accepted surgical resection during gestation immediately after the tumor was diagnosed. She decided to undergo RT and concomitant chemotherapy (TMZ) during pregnancy, subsequently delivered the full-term infant and got adjuvant chemotherapy (TMZ) afterward. The patient

FIGURE 1 | Main medical imaging and histopathology information of the pregnant GBM patient. (A) MRI images of the primary GBM prior to the first right parietal craniotomy that demonstrated a heterogeneous cystic and solid mass in the right parietal lobe and a shift of the midline structures to the left side (01/11/2017). (B) MRI images on the 3rd day after the first right parietal craniotomy that demonstrated a total resection of the mass, the marked surrounding edema and a shift of the midline structures to the left side remained (01/21/2017). (C) Histopathological features of the primary GBM. Hematoxylin and eosin (H & E) staining of the primary revealed the hyper-cellular astrocytic neoplasm. The features such as mitotic activity, microvascular proliferation, and pseudopalisading presented. The histopathological features indicated the primary tumor to be GBM. (D) Emergency CT scan when the patient was diagnosed with a recurrent tumor, prior to the second right parietal craniotomy which demonstrated a huge fresh mass of low density in the right parietal lobe surrounded by extensive edema, accompanied with a shift of midline structure and distortion of the right lateral ventricle (03/28/2017). (E) MRI images on the 3rd day after the second right parietal craniotomy which demonstrated a total resection of the recurrent tumor, the marked surrounding edema and a shift of the midline structures to the left side still remained (03/30/2018). (F) Histopathological features of the recurrent GBM. Hematoxylin and eosin (H & E) staining of the primary revealed the similar histopathological features with the primary tumor. (G) MRI images of the latest follow-up after multidisciplinary therapy (12/08/2018). The images demonstrated no signs of recurrence and smaller volume of the surrounding edema. The region of the tumor transformed into a capsule without enhancement. The disease remained stable.
### TABLE 1 | Defined cases of GBM in pregnancy published in the literature.

| Author/year          | Age | Weeks of gestation | Molecular confirmation | Treatment strategy                                                                 | Outcome                                                                 |
|----------------------|-----|--------------------|------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Mackenzie et al. (23) | 48  | 36 2/7 (Primary diagnosis of GBM) | NR                     | C/S + subsequent craniotomy, RT + adjuvant chemotherapy                              | Patient: Died after 9 months since first diagnosis, Infant: remained normally |
| McGrane et al. (5)   | 33  | 14 (Primary diagnosis of GBM)    | NR                     | Craniotomy, RT + concomitant TMZ chemotherapy (during pregnancy), C/S, Adjuvant chemotherapy (TMZ) | Patient: alive without recurrence (2 years FU), Infant: remained normally |
| Scarrott et al. (24)  | 32  | 24 (recurrent GBM)            | NR                     | Primary tumor (without pregnancy): Craniotomy + RT + concomitant chemotherapy (TMZ), Got pregnant | Patient: Died 5 months after delivery, Infant: remained normally |
| Nolan et al. (25)    | 23  | 2 (During adjuvant chemotherapy for primary GBM) | NR                     | Craniotomy, RT + concomitant chemotherapy (TMZ), Got pregnant, Continue chemotherapy (TMZ), Delivery | Patient: alive (6 months FU), Infant: remained normally |
| Flechl et al. (26)   | 37  | 3 weeks after the 2nd adjuvant chemotherapy | NR                     | Primary tumor: 1st Craniotomy + RT + concomitant and adjuvant chemotherapy, Recurrent tumor: 2nd Craniotomy + adjuvant chemotherapy (TMZ), Got pregnant | Patient: alive with distal progression (8 months FU), Infant: NR |
| Gulsen et al. (27)   | 30  | 7 (Primary diagnosis of GBM)   | NR                     | Primary tumor: 1st craniotomy (7th week of gestation, no adjuvant therapy), Recurrent tumor: 2nd craniotomy (24th week of gestation) + RT (27th week of gestation), C/S + 3rd craniotomy (no adjuvant chemotherapy) | Patient: Died 2 months after delivery, Infant: NR |
| Horowitz et al. (23) | 37  | 23 (Primary diagnosis of GBM)  | MGMT(-)                | Craniotomy, RT (During pregnancy), Adjuvant chemotherapy (TMZ) (postnatal), C/S + 3rd craniotomy (no adjuvant chemotherapy) | Patient: alive without recurrence (6 months FU), Infant: NR |
| Yust-Katz et al. (29) | NR  | NR                 | NR                     | Pregnant when the GBMs were diagnosed, Case 1, Craniotomy (during pregnancy), No RT/Chemotherapy (No RT), -Case 2, Craniotomy (during pregnancy + RT during pregnancy), No chemotherapy, C/S | Patient: NR, Infant: healthy |
| Al-Rasheedy et al. (9) | 36  | 18 (During adjuvant chemotherapy for primary GBM) | NR                     | RT + concomitant chemotherapy (TMZ), Adjuvant chemotherapy (TMZ), C/S (28 weeks of gestation)+ palliative TMZ treatment | Patient: died 2 weeks after delivery, Infant: remained normally |
| Taylan et al. (30)   | 24  | 24 (When the recurrent tumor was diagnosed) | NR                     | Primary tumor: Craniotomy + RT + concomitant chemotherapy (TMZ), Got pregnant, Tumor recurred: VP-Shunting+ betamethasone treatment, C/S + planned chemotherapy (TMZ) | Patient: No follow-up information, Infant: No follow-up information |

NR, Not Recorded; C/S, Cesarean Section; RT, Radiation Therapy; TMZ, Temozolomide; FU, Follow Up; GBM, Glioblastoma.

was alive without progression for 2 years, and the baby was healthy. It was a relatively satisfied outcome for management of GBM in pregnancy. With respect to another case reported in 2014 (28), the 23-week gravida was diagnosed with GBM, the mass was immediately resected. She accepted RT alone during pregnancy and followed postnatal adjuvant chemotherapy (TMZ). The patient was alive without recurrence for 6 months until the case was reported, while there is no information about the infant.
It is suggested that undergoing RT, concomitant and adjuvant chemotherapy with taking a risk for the fetus during pregnancy may elevate the survival of the patients, and no evidence of harm to the fetus was reported.

Considering the risk for the fetus, some of the gravidas refused taking RT or chemotherapy after the surgical resection. The patient of 2014 (27) was only 7-weeks pregnant when the tumor was diagnosed and a craniotomy was performed, the family rejected any adjuvant management until the tumor recurred in the 24th week of gestation, the second craniotomy was performed and RT was undergone 3 weeks later. Tumor recurred again in the 37th week of gestation, the cesarean section was performed in full term with a healthy infant being delivered. In the aforementioned situation, the simultaneous C/S and craniotomy are feasible in specific circumstances and diminishes the potentially harmful effect on the fetus of RT and chemotherapy. However, the risk of performing two operations at the same time is worth considering.

Notably, some patients got pregnant during the period of adjuvant treatment for GBM. The patient reported in 2012 (25) got pregnant during the period of concomitant chemotherapy (TMZ) treatment, the adjuvant TMZ treatment was continuously accomplished following the initial strategy. No abnormality was observed from the infant, and the patient was alive for 6 months when the case was published. The patient reported in 2013 (26) got surgical resection, RT and chemotherapy (TMZ) for the primary GBM, the tumor recurred, and a second surgery was performed followed with adjuvant chemotherapy, however, she got pregnant after complete adjuvant chemotherapy (TMZ) for the recurrent GBM. Cesarean section was performed in full term with a healthy infant being delivered, no treatment aiming the GBM was applied. The tumor progressed, then clinicians performed craniotomy again with chemotherapy (Fotemustine and Bevacizumab) undergoing. The patient was alive with distal progression when the case was reported.

**TABLE 2 | Postoperative Chemo-radiotherapy Strategy.**

| Chemotherapy    | Cycles       | Volume               | Date               |
|-----------------|--------------|----------------------|--------------------|
| Nimotuzumab     | concomitant  | 200 mg/time/week     | 2017.04.17–2017.05.28 |
| Temozolomide    | concomitant  | 75 mg/m²/day         | 2017.04.17–2017.05.28 |
| Vemurafenib     | 1 cycle      | 720 mg/time twice a day | 2017.06.09–2017.07.12 |
| Temozolomide    | 1st cycle    | 300 mg/day           | 2017.06.27–2017.06.31 |
| (Adjuvant)      | 2nd cycle    | 350mg/day            | 2017.07.24–2017.07.28 |
|                 | 3rd cycle    | 350mg/day            | 2017.10.12–2017.10.16 |
|                 | 4th cycle    | 350mg/day            | 2017.11.15–2017.11.19 |
|                 | 5th cycle    | 300mg/day            | 2017.12.17–2017.12.21 |
|                 | 6th cycle    | 300mg/day            | 2018.01.14–2018.01.18 |
| Radiotherapy    | PTV1 60Gy/2.0Gy/30F | PTV2 54Gy/1.8Gy/30F |                    |

**TABLE 3 | Major Findings of Genetic Variant Analysis by Gene Sequencing.**

| Testing gene                          | Result   |
|---------------------------------------|----------|
| MGMT methylation                      | None     |
| 1p Chromosome deletion                 | Positive |
| 19q Chromosome deletion                | None     |
| IDH1 Mutation                         | None     |
| TERT promoter C228T mutation          | None     |
| TERT promoter C250T mutation          | None     |
| BRAF V600E mutation                   | Positive |

**DISCUSSION**

GBM is the most aggressive brain tumor with infiltrating growth, which leads to difficulty of total resection (2, 31–33) and disease progression or recurrence (34). Once recurrence takes place, GBM becomes quickly fatal in the majority of cases (1, 35, 36). Therefore, newly diagnosed GBM requires multidisciplinary approaches to generate the best outcome. GBM during pregnancy is rare in current reports, and the strategy for managing pregnant GBM patients remains largely unknown. The role, safety, and especially the timing of treatment modalities for glioblastoma in the context of pregnancy are personalized for individuals at different stages of pregnancy (7, 23). According to our results and previous studies, we could draw a conclusion that surgical resection is always considered if the tumor is resectable. However, surgery alone results in poorer outcomes of short-termed recurrence compared with multimodal therapy. To date, there is no evidence shows exposure to RT or chemotherapy doing harm to the fetus. Besides, some patients get pregnant during the radiation or chemotherapeutic treatment for GBM causes unexpected difficulties for the regular treatment, contraception is highly recommended for the female GBM patients during the treatment procedure.

The reported outcomes of variant management for GBM during pregnancy are dramatically different. Survivals of the mother range from 2 to 24 months, none of the cases accepted delivery and craniotomy in the meantime and accepting adjuvant treatment afterward. The gravida reported in 2005 (23) was almost full-term when she was primarily diagnosed with GBM. She chose to take the risk of undergoing cesarean section (C/S) and craniotomy contemporarily. The concomitant RT and adjuvant chemotherapy were applied, but the patient died after 9 months with the infant remaining normal. In the aforementioned situation, the simultaneous C/S and craniotomy are feasible in specific circumstances and diminishes the potentially harmful effect on the fetus of RT and chemotherapy. However, the risk of performing two operations at the same time is worth considering.

**TABLE 2 | Postoperative Chemo-radiotherapy Strategy.**

| Chemotherapy    | Cycles       | Volume               | Date               |
|-----------------|--------------|----------------------|--------------------|
| Nimotuzumab     | concomitant  | 200 mg/time/week     | 2017.04.17–2017.05.28 |
| Temozolomide    | concomitant  | 75 mg/m²/day         | 2017.04.17–2017.05.28 |
| Vemurafenib     | 1 cycle      | 720 mg/time twice a day | 2017.06.09–2017.07.12 |
| Temozolomide    | 1st cycle    | 300 mg/day           | 2017.06.27–2017.06.31 |
| (Adjuvant)      | 2nd cycle    | 350mg/day            | 2017.07.24–2017.07.28 |
|                 | 3rd cycle    | 350mg/day            | 2017.10.12–2017.10.16 |
|                 | 4th cycle    | 350mg/day            | 2017.11.15–2017.11.19 |
|                 | 5th cycle    | 300mg/day            | 2017.12.17–2017.12.21 |
|                 | 6th cycle    | 300mg/day            | 2018.01.14–2018.01.18 |
| Radiotherapy    | PTV1 60Gy/2.0Gy/30F | PTV2 54Gy/1.8Gy/30F |                    |

**TABLE 3 | Major Findings of Genetic Variant Analysis by Gene Sequencing.**

| Testing gene                          | Result   |
|---------------------------------------|----------|
| MGMT methylation                      | None     |
| 1p Chromosome deletion                 | Positive |
| 19q Chromosome deletion                | None     |
| IDH1 Mutation                         | None     |
| TERT promoter C228T mutation          | None     |
| TERT promoter C250T mutation          | None     |
| BRAF V600E mutation                   | Positive |
gene sequencing for molecular features of the tumors and genetic therapy. Regarding this presenting case, not willing taking a risk for the fetus, the pregnant patient accepted surgical resection for the primary tumor without undergoing any concomitant radiation therapy or adjuvant chemotherapy, consequently, the tumor recurred in a short time. With undergoing multidisciplinary therapy including gene sequencing and BRAF-targeted treatment (Figure 2), she remained stable for 24 months since the tumor was diagnosed primarily even with recurrence. With regard to this case, the pregnant GBM patients obtained satisfactory lifetime with delivering healthy baby meanwhile. Although recent report declared pregnant GBM patients with 64 and 96 months of progression-free survival. The patient with 96 months was IDH1 mutant and the other patient with 64 months had MGMT methylation (37), which are both indicators of optimistic prognosis. To the best of our knowledge, this case is still the maximum lifetime for the pregnant GBM patients without IDH mutation and MGMT methylation. Therefore, this case encourages discussion on the most appropriate adjuvant therapy for pregnant GBM patients who have significant post-operative tumor residuum or progression, in addition, point out the importance of advanced genetic therapy.

Nowadays, more in-depth insights into genetic advances have contributed to a better understanding of the pathophysiology and molecular stratification of GBM (38, 39). The molecular alterations in GBM are extremely complicated. The mostly focused clinically relevant genetic alterations in GBMs include IDH mutations, 1p/19q co-deletion, epidermal growth factor receptor (EGFR) amplification, O-6-methylguanine-DNA methyltransferase (MGMT) methylation status and telomerase reverse transcriptase (TERT) promoter mutation (36, 40–42). Our presenting case showed no alteration in those genes, and MGMT methylation was identified as negative, indicating the traditional chemotherapy and targeting therapy would not undergo well. Moreover, Ki67 of the recurred GBM elevated to 30%+ from 10%+, which suggested the recurrent tumor possessing higher aggressive features compared with the primary one. Fortunately, the gene sequencing technique with wide coverage provided us with another potential approach for stabilizing the progression of the disease since BRAF V600E mutation was detected in the recurrent tumor. The nimotuzumab was administered to reduce the edema of the surrounding area of the postoperative tumor cavity, and also to elongate the period of stable disease. As previously reported, nimotuzumab in addition to standard treatment is well-tolerable and has increased survival in GBM patients with EGFR positive (43), we underwent nimotuzumab with temozolomide and RT contemporarily after the second craniotomy without the gene sequencing result coming out, even though the genetic test claimed EGFR negative in this patient afterwards.

With increasing prominence, BRAF-targeted therapies have shown efficacy in specific tumor entities (11, 12, 44). Direct targeting with BRAF inhibitors has been reported to be favorable for treating those malignant tumors harboring the BRAF V600E mutation (45, 46). In the view of central nervous system, the most commonly reported brain tumors with BRAF mutation include pleomorphic xanthoastrocytoma (PXA) (60%), extra-cerebellar pilocytic astrocytoma (20%) and ganglioglioma (20% to 60%) for low grade (WHO I-II), PXA with anaplastic features (60%) (21, 47–49) for higher grade (WHO III). Several rare CNS tumors such as craniopharyngioma (19, 50) and meningioma (51) were also reported containing BRAF mutation, following encouraging outcomes. As to high-grade brain tumors, recent reports about the GBM (48, 52, 53) and gliosarcoma (54) that manifest BRAF V600E mutation have been published. Of note, the outcomes of the GBMs with BRAF V600E that were treated with vemurafenib are optimistic according to the reports so far.

Meanwhile, the side-effect of vemurafenib is also reported in the clinical cases, for example, granulomatous hepatitis (55).
and cutaneous diseases (56). Accordingly, prior to the targeting therapy with vemurafenib for our patient, hepatic protection was undergone. Severe diffuse palpable follicular rashes presented without prediction, so the treatment had to be halted for 5 days, and the patient was recommended to wear protective clothing and take other measures such as using sunscreens containing UVA-protective agents to prevent photosensitivity. However, the vemurafenib was administered for only 1 cycle due to the iterative the diffuse palpable follicular rash afterwards, the patient complained the adverse event was intolerable and refused to accept the following treatment. The patient and her family were not able to afford the high cost of subsequent vemurafenib treat. Despite the side-effect, BRAF V600E mutation can be regarded as a potential hallmark indicating a relatively optimistic prognosis for the patients suffering from GBM because BRAF inhibitors such as vemurafenib extended the survival of GBM patients. We propose that BRAF mutation should be tested routinely for GBMs and the other malignant gliomas during the histopathological assay. Besides, with the revolution of genomics, gene sequencing has become a portion of multidisciplinary therapy, which would provide the physicians with adequate information guiding the therapeutic strategy. The novel targets such as BRAF might shed light on the pessimistic prognosis of GBM. However, further observation and potential adjustment is required to determine the optimal duration, dose, and combination of multidisciplinary treatment. On the other hand, the influence of targeted therapy on the maturity and development of the fetus is largely unknown due to the lack of reported cases.

CONCLUSION

We present here a significant case that suggests the personalized MDT comprising genetic therapy may provide the pregnant GBM patients with improved outcomes, it complements the evidence of the management for GBMs in pregnancy. The response to this presenting therapy indicates that BRAF V600E mutation is a favorable biomarker for GBM. The mortality of GBM might be reduced through genetic testing and vemurafenib targeted treatment. However, more studies must be conducted to confirm our observation.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of Xiangya Hospital Central South University. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

CQ, WL, YX, CZ, CW, YL, QX, and QL performed the surgical procedures. CQ, WL, CW, YL, and QX performed data collection and analysis. NJ and YL performed gene sequencing and target therapy. CQ, WL, and QL wrote the manuscript. QL supervised the entire work. CQ, WL, YX, CZ, CW, YL, QX, NJ, YL, and QL provided final approval for the version to be published. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by grants from the National Key Technology Research and Development Program of the Ministry of Science and Technology of China (Grant Number 2014BAI04B01) and the National Natural Science Foundation of China (Grant Number 81802974). Grant 2014BAI04B01 had a role in collection, analysis, and interpretation of data. Grant Number 81802974 had a role in writing the manuscript.

ACKNOWLEDGMENTS

All contributors to this study are included in the list of authors.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.522816/full#supplementary-material

SUPPLEMENTARY FIGURE 1 | MRI images prior to vemurafenib therapy (the radiotherapy and concomitant chemotherapy had been accomplished) (05/27/2017). (A,B) Axial MRI T1-weighted images with gadolinium-based contrast demonstrated no signs of recurrence, the surrounding edema subsided and the midline structures returned to the initial position. (C,F) Coronal and sagittal MRI T1-weighted images with gadolinium-based contrast demonstrated the consistent outcome. (D,E) Axial MRI T2-weighted images demonstrated edema around the tumor relived.

SUPPLEMENTARY FIGURE 2 | First regular follow-up MRI images after the multidisciplinary therapy (12/14/2017). (A,B) Axial MRI T1-weighted images with gadolinium-based contrast demonstrated no signs of recurrence, the volume of surrounding edema decreased. The region of the primary and recurrent tumor gradually transformed into a capsule without enhancement. (C–F) Coronal and sagittal MRI T1-weighted images with gadolinium-based contrast demonstrated the consistent outcome.

SUPPLEMENTARY FIGURE 3 | Second regular follow-up MRI images after multidisciplinary therapy (03/20/2018). (A,B) Axial MRI T1-weighted images with gadolinium-based contrast demonstrated no signs of recurrence, the volume of surrounding edema further decreased. The region of the primary and recurrent tumor gradually transformed into a capsule without enhancement. (C–F) Coronal and sagittal MRI T1-weighted images with gadolinium-based contrast demonstrated the consistent outcome.

SUPPLEMENTARY FIGURE 4 | Third regular follow-up MRI images of the latest follow-up after multidisciplinary therapy (06/09/2018). (A,B) Axial MRI T1-weighted images with gadolinium-based contrast demonstrated similar features with the second former follow-up results. (C–F) Coronal and sagittal MRI T1-weighted images with gadolinium-based contrast demonstrated the consistent outcome.
REFERENCES

1. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. (2016) 131:803–20. doi: 10.1007/s00401-016-1545-1

2. Tamimi AF, Juweid M. Epidemiology and outcome of glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma. Brisbane, QLD: Codon Publications (2017). p. 143–53. doi: 10.15586/codon.glioblastoma.2017.ch8

3. McGrane J, Bedford T, Kelly S. Successful pregnancy and delivery after concomitant temozolomide and radiotherapy treatment of glioblastoma multiforme. Clin Oncol (2012) 24:311. doi: 10.1016/j.clon.2012.01.005

4. Preusser M, Seywald S, Elandt K, Kurz C, Rottenfusser A, Dieckmann K, et al. Pilot study on sex hormone levels and fertility in women with malignant gliomas. J Neurooncol. (2012) 107:387–94. doi: 10.1007/s11060-011-0761-8

5. Jayasekera BA, Bacon AD, Whitfield PC. Management of glioblastoma multiforme in pregnancy. J Neurosurg. (2012) 116:1187–94. doi: 10.1093/jnci/djs066

6. Lew PS, Tan WC, Tan WK, Tan HK. Dilemmas in management of brain tumours in pregnancy. Ann Acad Med Singapore. (2015) 39:64–65. doi: 10.1111/acm.12525

7. Nolan B, Balakrishna M, George M. Exposure to temozolomide in the first trimester of pregnancy in a young woman with glioblastoma multiforme. World J Oncol. (2012) 3:286–7. doi: 10.4213/wjon570w

8. Flechl B, Hassler MR, Kopetzky G, Balcke P, Kurz C, Marosi C. Case report: pregnancy in a patient with recurrent glioblastoma. F1000Res. (2013) 2:246. doi: 10.2122/f1000research.2-246.v1

9. Himes BT, Ruff MW, Van Gompel JJ, Park SS, Galanis E, Kaufmann TJ, et al. Recurrent papillary craniosphenoidal with BRAF V600E mutation treated with dabrafenib: case report. J Neurosurg. (2018) 113:1–5. doi: 10.3171/2017.11.NS172373

10. Basto D, Trovisco V, Lopes JM, Martins A, Pardal F, Soares P, et al. Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol. (2005) 109:207–10. doi: 10.1007/s00401-004-0936-x

11. Donohue MJ, Santi M, Brose MS, Ma C, Resnick AC, Sievert AJ, et al. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol. (2010) 12:621–30. doi: 10.1093/neuonc/noq007

12. Ceccon G, Werner JM, Dunkl V, Tischerl C, Stoffels G, Brunn A, et al. Dabrafenib Treatment in a patient with an epithelioid glioblastoma and BRAF V600E mutation. Int J Mol Sci. (2018) 19:1090. doi: 10.3390/ijms1901090

13. MacKenzie AP, Levine G, Garry D, Figueroa R. Glioblastoma multiforme in pregnancy. J Matern Fetal Neonatal Med. (2005) 17:81–3. doi: 10.1080/14767050400287097

14. Scarratt LJ, Raina A, Madej T, Rajesh U. Recurrent glioblastoma multiforme in pregnancy. J Obstet Gynaecol. (2012) 32:704–5. doi: 10.3109/01443615.2012.697226

15. Horowitz DP, Wang TJ, Wuu CS, Feng W, Drassinower D, Lasala A, et al. Fetal radiation monitoring and dose minimization during intensity modulated radiation therapy for glioblastoma in pregnancy. J Neurooncol. (2014) 120:405–9. doi: 10.1007/s00401-014-1565-4

16. Yu-Stkatz S, de Groot JE, Liu D, Wu J, Yuan Y, Anderson MD, et al. Pregnancy and glioblastoma and melanoma. Neuro Oncol. (2014) 16:289–94. doi: 10.1093/neuonc/nou019

17. Taylor E, Akdemir A, Zeybek B, Ergenoglu AM, Yeniel AO. Recurrent glioblastoma brain tumor with hydrocephalus in pregnancy. J Obstet Gynaecol Res. (2015) 41:464–7. doi: 10.1111/jog.12546

18. Birbilis TA, Matis GK, Eftoridieris SG, Theodoropoulou EN, Sviridis E. Spinal metastasis of glioblastoma multiforme: an uncommon suspect? Spine. (2010) 35:E264–9. doi: 10.1097/ROS.0b013e3181c11748

19. Karcher S, Steiner HH, Ahmadi R, Zoubaa S, Vasvari G, Bauer H, et al. Different angiogenic phenotypes in primary and secondary glioblastomas. Int J Cancer. (2006) 118:2182–9. doi: 10.1002/ijc.21648

20. Nemani MV, Bell JR, Sabes RJ, Kuroda Y, Springer J. The natural history of extracranial metastasis from glioblastoma multiforme. J Neurooncol. (2011) 105:261–73. doi: 10.1007/s11060-011-0575-8

21. Wilson TA, Karajannis MA, Harter DH. Glioblastoma multiforme: State of the art and future therapies. Surg Neurol Int. (2014) 5:64. doi: 10.4103/2152-7806.132138

22. Davis ME. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs. (2016) 20:52–8. doi: 10.1188/16.CJON.S1.2-8

23. Kolay MA. Impact of molecular classification of glioblastoma to inform personalized treatment. J Pathol. (2014) 232:165–77. doi: 10.1002/path.4282

24. Singh P, Mantilla E, Sewell J, Hatangpa KJ, Pan E. Occurrence of glioma in pregnancy and the outlook for targeted therapies. Lancet Oncol. (2017) 18:e774–82. doi: 10.1016/S1470-2045(17)30234-0

25. Nolan B, Balakrishna M, George M. Exposure to temozolomide in the first trimester of pregnancy in a young woman with glioblastoma multiforme. World J Oncol. (2012) 3:286–7. doi: 10.4213/wjon570w

26. Flechl B, Hassler MR, Kopetzky G, Balcke P, Kurz C, Marosi C. Case report: pregnancy in a patient with recurrent glioblastoma. F1000Res. (2013) 2:244–50. doi: 10.3978/j.issn.2218-6751.2013.04.01

27. Haushild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. (2012) 380:358–65. doi: 10.1016/S0140-6736(12)60867-X

28. Himes BT, Ruff MW, Van Gompel JJ, Park SS, Galanis E, Kaufmann TJ, et al. Recurrent papillary craniosphenoidal with BRAF V600E mutation treated with dabrafenib: case report. J Neurosurg. (2018) 113:1–5. doi: 10.3171/2017.11.NS172373
42. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. *Science*. (2008) 321:1807–12. doi: 10.1126/science.1164382

43. Du XJ, Li XM, Cai LB, Sun JC, Wang SY, Wang XC, et al. Efficacy and safety of nimotuzumab in addition to radiotherapy and temozolomide for cerebral glioblastoma: a phase II multicenter clinical trial. *J Cancer*. (2019) 10:3214–23. doi: 10.7150/jca.30123

44. Hanahan D. Rethinking the war on cancer. *Lancet*. (2014) 383:558–63. doi: 10.1016/S0140-6736(13)62226-6

45. Garbe C, Eigentler TK. Vemurafenib. *Recent Results Cancer Res*. (2018) 211:77–89. doi: 10.1007/978-3-319-91442-8_6

46. Sharma A, Shah SR, Illum H, Dowell J. Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies. *Drugs*. (2012) 72:2207–22. doi: 10.2165/11640870-000000000-00000

47. Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. *PLoS ONE*. (2011) 6:e17948. doi: 10.1371/journal.pone.0017948

48. Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, Foreman NK. Epithelioid GBMs show a high percentage of BRAF V600E mutation. *Am J Surg Pathol*. (2013) 37:685–98. doi: 10.1097/PAS.0b013e318279c5e

49. Koelsche C, Wohrer A, Jeibmann A, Schittenhelm J, Schindler G, Preusser M, et al. Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. *Acta Neuropathol*. (2013) 125:891–900. doi: 10.1007/s00401-013-1100-2

50. Borrelli R, Chessman E, Stivaro S, Kamaly-Asl ID, Gnanalingham K, Kilday JP. Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature. *Childs Nerv Syst Aug*. (2018) 35:169–73. doi: 10.1007/s00381-018-3925-4

51. Mordechai O, Postovsky S, Vlodavsky E, Eran A, Constantini S, Dotan E, et al. Metastatic chabroid meningioma with BRAF V600E mutation and good response to personalized therapy: case report and review of the literature. *Pediatr Hematol Oncol*. (2013) 32:207–11. doi: 10.3109/08880018.2014.936058

52. Suzuki Y, Takahashi-Fujigasaki J, Akasaki Y, Matsushima S, Mori R, Karagiozov K, et al. BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review. *Brain Tumor Pathol*. (2016) 33:40–9. doi: 10.1007/s10014-015-0234-4

53. Takahashi Y, Akahane T, Sawada T, Ikeda H, Tempaku A, Yamauchi S, et al. Adult classical glioblastoma with a BRAF V600E mutation. *World J Surg Oncol*. (2015) 13:100. doi: 10.1186/s12957-015-0521-x

54. Wang L, Sun J, Li Z, Chen L, Fu Y, Zhao L, et al. Gliosarcomas with the BRAF V600E mutation: a report of two cases and review of the literature. *J Clin Pathol*. (2017) 70:1079–83. doi: 10.1136/jclinpath-2016-204620

55. Spengler EK, Kleiner DE, Fontana RJ. Vemurafenib-induced granulomatous hepatitis. *Hepatology*. (2017) 65:745–8. doi: 10.1002/hep.28692

56. Robinson GW, Orr BA, Gajjar A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. *BMC Cancer*. (2014) 14:258. doi: 10.1186/1471-2407-14-258

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Qin, Long, Zhang, Xie, Wu, Li, Xiao, Ji and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.